Browse by author
Lookup NU author(s): Professor Philip Sloan
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: Nuclear imaging plays a crucial role in lymphatic mapping of oral cancer. This evaluation represents a subanalysis of the original multicenter SENT trial data set, involving 434 patientswith T1-T2, N0, and M0 oral squamous cell carcinoma. The impact of acquisition techniques, tracer injection timing relative to surgery, and causes of false-negative rate were assessed.Methods: Three to 24 hours before surgery, all patients received a dose of Tc-99m-nanocolloid (10-175 MBq), followed by lymphoscintigraphy. According to institutional protocols, all patients underwent preoperative dynamic/static scan and/or SPECT/CT.Results: Lymphoscintigraphy identified 723 lymphatic basins. 1398 sentinel lymph nodes (SNs) were biopsied (3.2 SN per patient; range, 1-10). Dynamic scan allowed the differentiation of sentinel nodes from second tier lymph nodes. SPECT/CT allowed more accurate anatomical localization and estimated SN depth more efficiently. After pathological examination, 9.9% of the SN excised (138 of 1398 SNs) showed metastases. The first neck level (NL) containing SN+ was NL I in 28.6%, NL IIa in 44.8%, NL IIb in 2.8%, NL III in 17.1%, and NL IV in 6.7% of positive patients. Approximately 96% of positive SNs were localized in the first and second lymphatic basin visualized using lymphoscintigraphy. After neck dissection, the SN+ was the only lymph node containing metastasis in approximately 80% of patients.Conclusions: Best results were observed using a dynamic scan in combination with SPECT/CT. A shorter interval between tracer injection, imaging, and surgery resulted in a lower false-negative rate. At least 2 NLs have to be harvested, as this may increase the detection of lymphatic metastases.
Author(s): Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MFF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O'Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Gutierrez LMJ, Barbier L, Santamaria-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M
Publication type: Article
Publication status: Published
Journal: Clinical Nuclear Medicine
Year: 2016
Volume: 41
Issue: 7
Pages: 534-542
Print publication date: 01/07/2016
Acceptance date: 01/01/1900
ISSN (print): 0363-9762
ISSN (electronic): 1536-0229
Publisher: Lippincott Williams & Wilkins, Ltd.
URL: http://dx.doi.org/10.1097/RLU.0000000000001241
DOI: 10.1097/RLU.0000000000001241
Altmetrics provided by Altmetric
